Welcome to Jianke online pharmacy! Sign in Free registration
reminder:The pictures are the real photos of the original products taken by Jianke for reference only; In case of new packaging listing, there may be update lag, please take the physical object as the standard!
Baidu certification

Salmeterol ticasone inhalation powder spray (Seretide)

Seretide is used in combination for routine treatment of reversible obstructive airway diseases, including asthma in adults and children. This may include: Receive a long-term effective maintenance dose β Patients treated with receptor agonists and inhaled corticosteroids. Patients who are currently treated with inhaled corticosteroids but still have symptoms. Patients who receive regular treatment with bronchodilators but still need inhaled corticosteroids. Note: This product is suitable for 50 μ g/100 μ G specification is not applicable to adults and children with severe asthma. More role
App download minus 10 yuan
Common name:
Salmeterol ticasone inhalation powder spray
Product No.:
B14200007474
Approval No.:
H20150324 (inquired by the State Drug Administration)
Jianke price:
¥288.00
Product specification:
fifty μ g/250 μ G * 60 foam fifty μ g:100 μ G * 60 foam 50ug / 500ug * 28 foam fifty μ g/500 μ G * 60 foam fifty μ g/500 μ G * 60 foam + 500mg * 100s fifty μ g/250 μ G * 60 foam + 500mg * 100s
Manufacturer:
Glaxo Wellcome production (France)
number        Quantity:
Add to list
Tips:
This product is a prescription drug. Please buy it with the prescription paper; Delivered by Jianke offline drugstore
 
(for assistance, please call400-086-5111
Jianke promises:
Genuine guarantee
Bank remittance / transfer online payment
  • Product introduction
  • instructions
  • Qualification certificate
  • Relevant information
Product name Salmeterol ticasone inhalation powder spray (Seretide)
Main raw materials Salmeterol and fluticasone propionate.
Main role Seretide is used in combination for routine treatment of reversible obstructive airway diseases, including asthma in adults and children. This may include: Receive a long-term effective maintenance dose β Patients treated with receptor agonists and inhaled corticosteroids. Patients who are currently treated with inhaled corticosteroids but still have symptoms. Patients who receive regular treatment with bronchodilators but still need inhaled corticosteroids. Note: This product is suitable for 50 μ g/100 μ G specification is not applicable to adults and children with severe asthma.
Product specification fifty μ g/250 μ G * 60 foam
Usage and dosage This product is only for oral inhalation. Patients should be made aware that this product must be used every day to obtain the desired benefits, even when it is asymptomatic. The patient should be re evaluated regularly by the doctor to maintain the best dose of the received product, and the dose of the product can be changed only at the suggestion of the doctor. The dose should be gradually adjusted to the minimum maintenance dose that can effectively control symptoms. When the minimum dose of combined drugs can maintain the control of symptoms, the next step is to try inhaled corticosteroids alone. As an option, if the doctor thinks it can control the disease, the product can be gradually reduced to once a day for patients who need long-term agonists. In the case of once daily medication, patients who often have symptoms at night should inhale this product at night; For patients who often have symptoms during the day, inhale this product in the morning. Patients should be prescribed this product containing an appropriate dose of fluticasone propionate according to the severity of the disease. If the therapeutic dose required by individual patients is not within the recommended dosage of this product, the doctor should prescribe an appropriate dose for them β- Agonists and / or corticosteroids. Recommended dose: Adults and adolescents aged 12 and over: 1 inhalation at a time (50 μ G salmeterol and 250 μ G fluticasone propionate), twice a day. Children aged 4 and over: 1 inhalation each time (50 μ G salmeterol and 100 μ G fluticasone propionate), twice a day. There is no information on the use of this product by children under 4 years old. Special patient groups: the elderly or patients with renal damage do not need to adjust the dose. There is no data on the use of seretide in patients with liver damage. Note: This product is suitable for 50 μ g/100 μ G specification is not applicable to adults and children with severe asthma.
manufacturing enterprise Glaxo Wellcome production (France)
Jianke commitment
  • Genuine guarantee, formal invoice

    Jianke.com is an approved (B2C) Internet drug legitimate business enterprise in Guangdong Province. It signs a direct supply agreement with the manufacturer and can issue formal invoices for the purchased goods.

  • Private packaging, privacy protection

    When jianke.com packages and delivers goods, the appearance of the packing box only displays the necessary information for delivery, and the name of the purchased goods will not appear. The specific shopping list is in the package to protect the privacy of customers.

  • Efficient logistics and safe arrival

    All products of jianke.com adopt the door-to-door distribution mode of third-party logistics. They are delivered to the nearest warehouse according to your distribution address, so as to deliver them to you on time.

  • Three warehouses to ensure inventory

    Jianke.com has three warehouses in Guangzhou, Dongguan and Wuhan, equipped with first-class equipment, constant temperature and humidity to ensure drug quality. Specially assigned person to manage and ensure product inventory.

[drug name] Salmeterol ticasone inhalation powder spray (Seretide)

[common name] Salmeterol ticasone inhalation powder spray

[specification and model] fifty μ g/250 μ G * 60 foam

[manufacturer] Glaxo Wellcome production (France)

[drug type] Western medicine

[approval No.] H20150324

[validity period] 24 months

[functional indications] Seretide is used in combination for routine treatment of reversible obstructive airway diseases, including asthma in adults and children. This may include: Receive a long-term effective maintenance dose β Patients treated with receptor agonists and inhaled corticosteroids. Patients who are currently treated with inhaled corticosteroids but still have symptoms. Patients who receive regular treatment with bronchodilators but still need inhaled corticosteroids. Note: This product is suitable for 50 μ g/100 μ G specification is not applicable to adults and children with severe asthma.

[usage and dosage] This product is only for oral inhalation. Patients should be made aware that this product must be used every day to obtain the desired benefits, even when it is asymptomatic. The patient should be re evaluated regularly by the doctor to maintain the best dose of the received product, and the dose of the product can be changed only at the suggestion of the doctor. The dose should be gradually adjusted to the minimum maintenance dose that can effectively control symptoms. When the minimum dose of combined drugs can maintain the control of symptoms, the next step is to try inhaled corticosteroids alone. As an option, if the doctor thinks it can control the disease, the product can be gradually reduced to once a day for patients who need long-term agonists. In the case of once daily medication, patients who often have symptoms at night should inhale this product at night; For patients who often have symptoms during the day, inhale this product in the morning. Patients should be prescribed this product containing an appropriate dose of fluticasone propionate according to the severity of the disease. If the therapeutic dose required by individual patients is not within the recommended dosage of this product, the doctor should prescribe an appropriate dose for them β- Agonists and / or corticosteroids. Recommended dose: Adults and adolescents aged 12 and over: 1 inhalation at a time (50 μ G salmeterol and 250 μ G fluticasone propionate), twice a day. Children aged 4 and over: 1 inhalation each time (50 μ G salmeterol and 100 μ G fluticasone propionate), twice a day. There is no information on the use of this product by children under 4 years old. Special patient groups: the elderly or patients with renal damage do not need to adjust the dose. There is no data on the use of seretide in patients with liver damage. Note: This product is suitable for 50 μ g/100 μ G specification is not applicable to adults and children with severe asthma.

[adverse reactions] A list of all adverse reactions associated with a single component (salmeterol cinoate, fluticasone propionate) is given below. Compared with the characteristics of single component adverse events, no other adverse reactions related to compound preparation were found. (see the inner packaging manual for details)

[precautions] 1. The treatment of reversible obstructive airway disease should follow the conventional ladder scheme, and the patient's response should be monitored through pulmonary function test in clinic. 2. Seretide is not suitable for the relief of acute symptoms, but should use rapid and short-acting bronchodilators (such as salbutamol). Patients should be advised to carry drugs that can quickly relieve symptoms at any time. 3. If the use of short acting bronchodilators is increased to alleviate asthma symptoms, it indicates that the control of asthma is not satisfactory. 4. The sudden and progressive deterioration of asthma control may be life-threatening. A doctor should be invited to recheck the patient and consider whether to increase corticosteroid treatment. Similarly, when the current dose of seretide is insufficient to control reversible obstructive airway disease, the patient should also check with a doctor. 5. At the same time, other corticosteroid therapies should be considered, and antibiotics should be added in case of infection. 6. Do not suddenly interrupt the treatment of seretide. 7. Like all inhaled corticosteroids, Seretide should be used with caution in patients with active or stationary pulmonary tuberculosis. 8. Patients with hyperthyroidism should use Seretide with caution. 9. Any inhaled corticosteroids may cause systemic reactions, especially long-term high-dose use, but their occurrence is much less than that of oral corticosteroids. Possible systemic effects include adrenal suppression, delayed development in children and adolescents, decreased bone mineral density, cataract and glaucoma. Therefore, it is important to adjust the dose of inhaled corticosteroids to the minimum control that can maintain effective control. 10. It is recommended to receive inhaled corticosteroids for a long time. (see the inner packaging instructions for details) please read the instructions carefully and follow the doctor's instructions.

[taboo] Do not use if you have a history of allergy to any of the ingredients in this product. This product contains lactose. It is forbidden for patients allergic to lactose and milk.

[listing Permit Holder] Glaxowellcomeproduction (France)

[packaging unit] box

[main ingredients] Salmeterol and fluticasone propionate.

[character] The first mock exam is white or white like powder, sealed in aluminum foil, and the aluminum foil is wrapped in a plastic device. This device is called a "nano". The patient inhaled the drug through the suction nozzle of the quasi dispenser.

[applicable population] unlimited

[medication for pregnant and lactating women] 1. During pregnancy and lactation, medication should only be considered when the expected benefit to the mother exceeds any possible harm to the fetus or child. 2. There is not enough experience in the use of salmeterol and fluticasone propionate during human pregnancy and lactation. 3. In the study of animal reproductive toxicity, whether alone or in combination, systemic exposure to excessive & beta; Both 2-adrenoceptor agonists and glucocorticoids were found to have expected effects on the fetus. 4. In the extensive clinical experience of using these two kinds of drugs, there is no evidence that the above phenomena are related to the therapeutic dose. Neither salmeterol nor fluticasone propionate showed potential reproductive toxicity. 5. After inhaling the therapeutic dose, the plasma concentrations of salmeterol and fluticasone propionate are very low, so the concentration in human milk is likely to be correspondingly low. This has been demonstrated in studies of lactating animals, where drug concentrations detected in milk are very low. There is no information on human milk.

[medication for children] Not yet clear.

[medication for elderly patients] Not yet clear.

[storage] Seal and store in a dry place.

Praise degree

zero%

    reminder

    Dear customer:

    In case of emergency, please call the ordering hotline400-086-5111Consult a health care professional pharmacist.

    Salmeterol ticasone inhalation powder spray (Seretide)

    ¥288.00

    reminder

    To ensure your privacy, please enter the verification code and click "confirm callback". Our customer service staff will call back the phone number you entered later!

    Please enter the correct verification code!
    Loding...
    Can't see clearly. Change one

    Dear customer:

    Your callback failed this time. Please re-enter the verification code to try. Thank you!